AstraZeneca (NYSE:AZN)
CEO Pascal Soriot is pulling out all the stops, and repeatedly pulling
out the checkbook, to rebuild the future prospects of this lagging Big
Pharma company. Having spent nearly $1 billion on Omthera and Pearl
Therapeutics earlier this year, AstraZeneca has announced yet another
deal – this time a potentially $500 million deal for an early-stage
company in the hot oncology immunotherapy space.
Read more here:
http://www.investopedia.com/stock-analysis/082613/astrazeneca-goes-back-ma-well-yet-again-azn-bmy-mrk-rhhby.aspx
No comments:
Post a Comment